Registry for Renal Artery Fibromuscular Dysplasia
Official title: A Prospective Study of the Renal Artery Fibromuscular Dysplasia Registry in China
Run by Shanghai Jiao Tong University School of Medicine · NCT05363748 · Data updated 2026-11-12
This study is creating a registry to learn more about renal artery fibromuscular dysplasia in patients in China, including what causes it and how to manage it better.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Shanghai Jiao Tong University School of Medicine Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | October 1, 2021 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2036 |
| Registry record updated | November 18, 2023 |
| Trial ID | NCT05363748 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients diagnosed with renal artery FMD, including those with atypical presentations, and individuals younger than 18 years with established FMD.
✕Probably not a fit
Patients who do not have a confirmed diagnosis of renal artery FMD or those with underlying syndromes like Williams syndrome or Neurofibromatosis may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to create a registry for patients diagnosed with renal artery fibromuscular dysplasia (FMD) in China. It seeks to describe the characteristics of FMD, identify environmental and hormonal factors associated with its onset and progression, and assess baseline characteristics that may increase the risk of complications such as dissections or strokes. The study will utilize imaging modalities like CT-angiography and MR-angiography to confirm diagnoses and gather data for analysis. The ultimate goal is to develop evidence-based management algorithms for patients with this condition.
Why it matters
Potential benefit: If successful, this registry could lead to improved understanding and management of renal artery FMD, potentially reducing complications for patients.
How similar studies have gone: While there have been registries for FMD in other populations, this specific approach focusing on the Asian demographic is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Informed consent; 2. Patients diagnosed with renal artery fibromuscular dysplasia (FMD), i.e. at least one string-of-beads (multifocal FMD) or focal stenosis (focal FMD). The diagnosis needs to be confirmed by at least one of the following imaging modalities: CT-angiography, MR-angiography or catheter-based angiography; 3. Patients with so-called "atypical renal artery FMD" or "renal artery FMD-like presentation", i.e. patients presenting with at least one dissection or 2 aneurysms \< 60-year-old, in the absence string-of-beads, focal stenosis or evidence of inherited arteriopathy; 4. Patients with established renal artery FMD younger than 18 years, without evidence of underlying syndromes such as Williams syndrome, Alagille syndrome or type 1 Neurofibromatosis; Exclusion Criteria: 1\. Not eligible for inclusion or in situations considered unqualified for the study by the investigator;
Where it's running
-
Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Principal investigator: Jiguang Wang, PhD — Ruijin Hospital
- Study coordinator: Jiguang Wang, MD, PhD
- Email: jiguangw@163.com
- Phone: +86-21-64370045
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.